Zacks: Analysts Anticipate American Renal Associates (ARA) Will Post Earnings of $0.17 Per Share

Analysts forecast that American Renal Associates (NYSE:ARA) will announce earnings per share of $0.17 for the current fiscal quarter, according to Zacks. Two analysts have made estimates for American Renal Associates’ earnings, with the highest EPS estimate coming in at $0.19 and the lowest estimate coming in at $0.15. American Renal Associates reported earnings per share of $0.16 during the same quarter last year, which would suggest a positive year over year growth rate of 6.3%. The company is scheduled to issue its next quarterly earnings report on Tuesday, August 14th.

On average, analysts expect that American Renal Associates will report full year earnings of $0.70 per share for the current year, with EPS estimates ranging from $0.66 to $0.75. For the next financial year, analysts expect that the business will report earnings of $0.78 per share, with EPS estimates ranging from $0.65 to $0.90. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover American Renal Associates.

American Renal Associates (NYSE:ARA) last posted its quarterly earnings results on Tuesday, May 8th. The company reported $0.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.02. American Renal Associates had a return on equity of 16.88% and a net margin of 0.60%. The firm had revenue of $194.67 million for the quarter, compared to the consensus estimate of $189.10 million. During the same period in the previous year, the business earned $0.07 earnings per share. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year.

ARA has been the topic of a number of analyst reports. Zacks Investment Research downgraded American Renal Associates from a “hold” rating to a “sell” rating in a research note on Tuesday, January 23rd. Leerink Swann downgraded American Renal Associates from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $17.00 to $27.00 in a research note on Thursday, March 8th.

Shares of American Renal Associates traded down $0.16, reaching $14.87, during trading on Thursday, Marketbeat.com reports. The company’s stock had a trading volume of 135,500 shares, compared to its average volume of 176,699. The company has a debt-to-equity ratio of 4.63, a current ratio of 1.15 and a quick ratio of 1.10. American Renal Associates has a 12-month low of $14.64 and a 12-month high of $15.25. The company has a market cap of $487.54 million, a PE ratio of 24.87, a price-to-earnings-growth ratio of 0.73 and a beta of 2.10.

Several institutional investors have recently bought and sold shares of the stock. Element Capital Management LLC purchased a new stake in shares of American Renal Associates in the first quarter valued at approximately $263,000. Barclays PLC boosted its position in American Renal Associates by 23.9% during the first quarter. Barclays PLC now owns 52,295 shares of the company’s stock worth $986,000 after purchasing an additional 10,093 shares in the last quarter. A.R.T. Advisors LLC purchased a new stake in American Renal Associates during the first quarter worth $354,000. OppenheimerFunds Inc. purchased a new stake in American Renal Associates during the first quarter worth $5,270,000. Finally, Dimensional Fund Advisors LP boosted its position in American Renal Associates by 96.9% during the first quarter. Dimensional Fund Advisors LP now owns 255,166 shares of the company’s stock worth $4,810,000 after purchasing an additional 125,561 shares in the last quarter. Hedge funds and other institutional investors own 91.50% of the company’s stock.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply